The discriminative stimulus properties of methylphenidate in C57BL/6J mice

Behavioural Pharmacology

Volumn 22, Issue 1, 2011, Pages 14-22

  McGovern, Robin W ^a   Middaugh, Lawrence D ^a   Patrick, Kennerly S ^a   Griffin, William C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Drug discrimination; Methylphenidate; Mouse

Indexed keywords

METHYLPHENIDATE;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; C57BL 6 MOUSE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ABUSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; ISOMER; MOTOR ACTIVITY; MOUSE; NONHUMAN;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CUES; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; METHYLPHENIDATE; MICE; MOTOR ACTIVITY;

EID: 78651385885     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283423d92     Document Type: Article

References (54)

1. Askenasy EP, Taber KH, Yang PB, Dafny N (2007). Methylphenidate (Ritalin): behavioral studies in the rat. Int J Neurosci 117:757-794.
2. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, et al. (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60:1111-1120.
3. Biederman J, Faraone SV (2002). Current concepts on the neurobiology of attention-deficit/hyperactivity disorder. J Atten Disord 6 (Suppl 1):S7-S16.
4. Biederman J, Faraone SV (2005). Attention-deficit hyperactivity disorder. Lancet 366:237-248.
5. Bondareva TS, Young R, Glennon RA (2002). Central stimulants as discriminative stimuli. Asymmetric generalization between (-)ephedrine and S( + )methamphetamine. Pharmacol Biochem Behav 74:157-162.
6. Callahan PM, De la Garza R II, Cunningham KA (1994). Discriminative stimulus properties of cocaine: modulation by dopamine D1 receptors in the nucleus accumbens. Psychopharmacology (Berl) 115:110-114.
7. Colpaert FC (1999). Drug discrimination in neurobiology. Pharmacol Biochem Behav 64:337-345.
8. Czoty PW, Makriyannis A, Bergman J (2004). Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) 175:170-178.
9. Darredeau C, Barrett SP, Jardin B, Pihl RO (2007). Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 22:529-536.
10. Davids E, Zhang K, Tarazi FI, Baldessarini RJ (2002). Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6- hydroxydopamine lesioning. Psychopharmacology (Berl) 160:92-98. (Pubitemid 34169830)
11. Desai RI, Paronis CA, Martin J, Desai R, Bergman J (2010). Monoaminergic psychomotor stimulants: discriminative-stimulus effects and dopamine efflux. J Pharmacol Exp Ther 333:834-843.
12. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, Ding YS, Logan J (1999). Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 146:93-100.
13. Gaytan O, al-Rahim S, Swann A, Dafny N (1997). Sensitization to locomotor effects of methylphenidate in the rat. Life Sci 61:101-107.
14. Godfrey J (2009). Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 23:194-205.
15. Grant KA (1999). Strategies for understanding the pharmacological effects of ethanol with drug discrimination procedures. Pharmacol Biochem Behav 64:261-267.
16. Griffin WC III, Novak AJ, Middaugh LD, Patrick KS (2010). The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice. Pharmacol Biochem Behav 95:267-272.
17. Halberda JP, Middaugh LD, Gard BE, Jackson BP (1997). DAD1 and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats. Synapse 26:81-92.
18. Heal DJ, Pierce DM (2006). Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20:713-738.
19. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002). Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156.
20. Hodge CW, Grant KA, Becker HC, Besheer J, Crissman AM, Platt DM, et al. (2006). Understanding how the brain perceives alcohol: neurobiological basis of ethanol discrimination. Alcohol Clin Exp Res 30:203-213.
21. Kollins SH, MacDonald EK, Rush CR (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68:611-627.
22. Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK (2009). Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl) 204:73-83.
23. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA (2006). Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 84:135-143.
24. Kuczenski R, Segal DS (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037. (Pubitemid 27176139)
25. Kuczenski R, Segal DS (2001). Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296:876-883.
26. Kuczenski R, Segal DS (2005). Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 57:1391-1396.
27. Li SM, Campbell BL, Katz JL (2006). Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J Pharmacol Exp Ther 317:1088-1096.
28. Markowitz JS, Patrick KS (2008). Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28 (3 Suppl 2):S54-S61.
29. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006). A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16:687-698.
30. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK (2004). Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health 35:501-504.
31. McCabe SE, Cranford JA, Morales M, Young A (2006). Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. J Stud Alcohol 67:529-537.
32. McDougall SA, Collins RL, Karper PE, Watson JB, Crawford CA (1999). Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp Clin Psychopharmacol 7:208-218.
33. Middaugh LD, Favara JP, Boggan WO, Stringer AJ (1988). Discriminative properties of phencyclidine in mice: generalization to ketamine and monohydroxy metabolites. Psychopharmacology (Berl) 96:381-384.
34. Middaugh LD, McGroarty KK, Groseclose CH, Adinoff B (1998). Cocaine discrimination: relationship to local anesthetics and monoamine uptake inhibitors in C57BL/6 mice. Psychopharmacology (Berl) 136:44-49.
35. Middaugh LD, Kelley BM, Cuison ER Jr, Groseclose CH (1999). Naltrexone effects on ethanol reward and discrimination in C57BL/6 mice. Alcohol Clin Exp Res 23:456-464.
36. Okie S (2006). ADHD in adults. N Engl J Med 354:2637-2641.
37. Overton DA, Shen CF (1988). Comparison of four-drug discriminations in training compartments with four identical levers versus four different responses manipulanda. Pharmacol Biochem Behav 30:879-888.
38. Patrick KS, Caldwell RW, Ferris RM, Breese GR (1987). Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152-158.
39. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, et al. (2007). Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346-353.
40. Patrick KS, Straughn AB, Perkins JS, Gonzalez MA (2009). Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol 24:1-17.
41. Perkins AN, Eckerman DA, MacPhail RC (1991). Discriminative stimulus properties of triadimefon: comparison with methylphenidate. Pharmacol Biochem Behav 40:757-761.
42. Schweri MM, Deutsch HM, Massey AT, Holtzman SG (2002). Biochemical and behavioral characterization of novel methylphenidate analogs. J Pharmacol Exp Ther 301:527-535.
43. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR (2006). Using drugdiscrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 1:1194-1206.
44. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005). Reinforcing effects of methylphenidate: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 177:349-355.
45. Suzuki T, Fukuoka Y, Mori T, Miyatake M, Narita M (2004). Behavioral sensitization to the discriminative stimulus effects of methamphetamine in rats. Eur J Pharmacol 498:157-161. (Pubitemid 39208075)
46. Teo SK, Stirling DI, Thomas SD, Khetani VD (2003). Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol Biochem Behav 74:747-754.
47. Valvassori SS, Frey BN, Martins MR, Reus GZ, Schimidtz F, Inacio CG, et al. (2007). Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behav Pharmacol 18:205-212.
48. Volkow ND, Swanson JM (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160: 1909-1918.
49. Volkow ND, Fowler JS,Wang GJ, Ding YS, Gatley SJ (2002). Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 12:557-566.
50. Williard RL, Middaugh LD, Zhu HJ, Patrick KS (2007). Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18:39-51.
51. Wood DM, Emmett-Oglesby MW (1989). Mediation in the nucleus accumbens of the discriminative stimulus produced by cocaine. Pharmacol Biochem Behav 33:453-457.
52. Wooters TE, Neugebauer NM, Rush CR, Bardo MT (2008). Methylphenidate enhances the abuse-related behavioral effects of nicotine in rats: intravenous self-administration, drug discrimination, and locomotor cross-sensitization.
53. Neuropsychopharmacology 33:1137-1148.
54. Zhu HJ, Patrick KS, Yuan HJ,Wang JS, Donovan JL, DeVane CL, et al. (2008). Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241-1248.